# Nanocrystalline Megestrol Acetate for the Treatment of Anorexia-Cachexia Syndrome in Extensive-Stage Small Cell Lung Cancer: A Prospective, Open-Label, Single-Arm Phase II Clinical Study

> **NCT06909383** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Guangzhou Institute of Respiratory Disease** · enrollment: 41 (estimated)

## Conditions studied

- Extensive-stage Small Cell Lung Cancer (ES-SCLC)
- Cancer - Associated Anorexia - Cachexia Syndrome

## Interventions

- **DRUG:** Nanocrystalline megestrol acetate

## Key facts

- **NCT ID:** NCT06909383
- **Lead sponsor:** Guangzhou Institute of Respiratory Disease
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-06-01
- **Primary completion:** 2026-06-01
- **Final completion:** 2026-12-31
- **Target enrollment:** 41 (ESTIMATED)
- **Last updated:** 2025-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06909383

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06909383, "Nanocrystalline Megestrol Acetate for the Treatment of Anorexia-Cachexia Syndrome in Extensive-Stage Small Cell Lung Cancer: A Prospective, Open-Label, Single-Arm Phase II Clinical Study". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT06909383. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*